TAC1 and depressive disorder: Alongside traditional self-reported assessments of pain intensity, functional disability, quality of life, depression, anxiety and stress, the trial incorporates objective physiological markers such as cortisol, β-endorphins, substance-P, IL-6, CRP and HRV.